NCT05564780View on ClinicalTrials.gov

Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension

NANot yet recruitingINTERVENTIONAL

Enrollment

20,000

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Cardiovascular Diseases

Interventions

DRUG

RASI and/or a single pill combination based RASI

The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.

All Listed Sponsors

lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

NCT05564780 - Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension | Biotech Hunter | Biotech Hunter